Matches in SemOpenAlex for { <https://semopenalex.org/work/W1844018813> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W1844018813 endingPage "13" @default.
- W1844018813 startingPage "207" @default.
- W1844018813 abstract "The NFkappaB signalling pathway plays an important role in chemoresistance and decreased apoptosis. One indirect way to inhibit the NFkappaB pathway is to slow down the proteasomal degradation of its inhibitor IkappaB, thus preventing NFkappaB from translocation into the nucleus. Hence, the effect of the proteasome inhibitor bortezomib (Velcade) on the cell proliferation of the MV3, FemX-1 and G361 human melanoma cell lines and its action in combination with the PPAR-gamma agonist rosiglitazone or the mistletoe lectin ML-I, both having anti-proliferative effects on melanoma cells in single agent use, was investigated.Proliferation of melanoma cells under the different treatment regimes over a broad concentration range (0.0001-100 microg/ml) was assessed by means of the XTT cell proliferation assay.At a concentration of 0.1 microg/ml bortezomib significantly reduced the proliferation rate of all melanoma cells to 1-13% of the control, which was mediated through increased apoptosis and inhibition of NFkappaB expression. Furthermore, the combination of bortezomib and rosiglitazone was the most potent and increased the effectiveness against melanoma cell growth by 63-71% (compared to single use of rosiglitazone) and by 27-39% (compared to single use of bortezomib), respectively.This combination strategy might be a promising approach for future melanoma therapy." @default.
- W1844018813 created "2016-06-24" @default.
- W1844018813 creator A5057382999 @default.
- W1844018813 creator A5061419899 @default.
- W1844018813 creator A5062826138 @default.
- W1844018813 creator A5080444236 @default.
- W1844018813 date "2007-03-14" @default.
- W1844018813 modified "2023-09-26" @default.
- W1844018813 title "The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells." @default.
- W1844018813 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17352234" @default.
- W1844018813 hasPublicationYear "2007" @default.
- W1844018813 type Work @default.
- W1844018813 sameAs 1844018813 @default.
- W1844018813 citedByCount "15" @default.
- W1844018813 countsByYear W18440188132012 @default.
- W1844018813 countsByYear W18440188132015 @default.
- W1844018813 countsByYear W18440188132017 @default.
- W1844018813 crossrefType "journal-article" @default.
- W1844018813 hasAuthorship W1844018813A5057382999 @default.
- W1844018813 hasAuthorship W1844018813A5061419899 @default.
- W1844018813 hasAuthorship W1844018813A5062826138 @default.
- W1844018813 hasAuthorship W1844018813A5080444236 @default.
- W1844018813 hasConcept C126322002 @default.
- W1844018813 hasConcept C170493617 @default.
- W1844018813 hasConcept C185592680 @default.
- W1844018813 hasConcept C190283241 @default.
- W1844018813 hasConcept C27740335 @default.
- W1844018813 hasConcept C2776364478 @default.
- W1844018813 hasConcept C2777478702 @default.
- W1844018813 hasConcept C2777658100 @default.
- W1844018813 hasConcept C2778367456 @default.
- W1844018813 hasConcept C2778938600 @default.
- W1844018813 hasConcept C2780152017 @default.
- W1844018813 hasConcept C502942594 @default.
- W1844018813 hasConcept C55493867 @default.
- W1844018813 hasConcept C62112901 @default.
- W1844018813 hasConcept C71924100 @default.
- W1844018813 hasConcept C98274493 @default.
- W1844018813 hasConceptScore W1844018813C126322002 @default.
- W1844018813 hasConceptScore W1844018813C170493617 @default.
- W1844018813 hasConceptScore W1844018813C185592680 @default.
- W1844018813 hasConceptScore W1844018813C190283241 @default.
- W1844018813 hasConceptScore W1844018813C27740335 @default.
- W1844018813 hasConceptScore W1844018813C2776364478 @default.
- W1844018813 hasConceptScore W1844018813C2777478702 @default.
- W1844018813 hasConceptScore W1844018813C2777658100 @default.
- W1844018813 hasConceptScore W1844018813C2778367456 @default.
- W1844018813 hasConceptScore W1844018813C2778938600 @default.
- W1844018813 hasConceptScore W1844018813C2780152017 @default.
- W1844018813 hasConceptScore W1844018813C502942594 @default.
- W1844018813 hasConceptScore W1844018813C55493867 @default.
- W1844018813 hasConceptScore W1844018813C62112901 @default.
- W1844018813 hasConceptScore W1844018813C71924100 @default.
- W1844018813 hasConceptScore W1844018813C98274493 @default.
- W1844018813 hasIssue "1A" @default.
- W1844018813 hasLocation W18440188131 @default.
- W1844018813 hasOpenAccess W1844018813 @default.
- W1844018813 hasPrimaryLocation W18440188131 @default.
- W1844018813 hasRelatedWork W1487698348 @default.
- W1844018813 hasRelatedWork W1586597239 @default.
- W1844018813 hasRelatedWork W1968980738 @default.
- W1844018813 hasRelatedWork W1975160900 @default.
- W1844018813 hasRelatedWork W2001480066 @default.
- W1844018813 hasRelatedWork W2001676296 @default.
- W1844018813 hasRelatedWork W2005975820 @default.
- W1844018813 hasRelatedWork W2013660816 @default.
- W1844018813 hasRelatedWork W2029212596 @default.
- W1844018813 hasRelatedWork W2031694725 @default.
- W1844018813 hasRelatedWork W2034074585 @default.
- W1844018813 hasRelatedWork W2047591801 @default.
- W1844018813 hasRelatedWork W2050352100 @default.
- W1844018813 hasRelatedWork W2091321756 @default.
- W1844018813 hasRelatedWork W2096735689 @default.
- W1844018813 hasRelatedWork W2121001769 @default.
- W1844018813 hasRelatedWork W2131595439 @default.
- W1844018813 hasRelatedWork W2150972506 @default.
- W1844018813 hasRelatedWork W2152949552 @default.
- W1844018813 hasRelatedWork W2167361262 @default.
- W1844018813 hasVolume "27" @default.
- W1844018813 isParatext "false" @default.
- W1844018813 isRetracted "false" @default.
- W1844018813 magId "1844018813" @default.
- W1844018813 workType "article" @default.